-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 26th the multinational pharmaceutical giant was the first to report annual results, with global COVID-19 sales reaching $48.7 billion, including $11.9 billion in emerging markets, up 1 percent, and 16 percent in China to $2.6 billion.
's generics business unit, Sanders, had a turnover of $9.6 billion, and while sales rose 2 percent, overall sales fell 1 percent because of price factors, particularly in the U.S., and the biosimilars component surged 19 percent to $1.9 billion.
's innovative pharmaceutical business hit a new high of $39 billion, up 3.4 percent from a year earlier.
novart innovative drug Top20 small molecule drugs accounted for about 65%, cancer drugs accounted for 40%.
Shakubaqu/Pythatan complex grew 45 percent to nearly $2.5 billion, the small molecule cancer drug ribociclib increased 43 percent to $650 million, the Dalafini/Qumetini complex also maintained a 15 percent high growth rate of $1.5 billion, and gene therapy Zolgensma surged 155 percent to $920 million.
picture below is details of Novaral's innovative drug Top20.
it's worth noting that while global sales of gene therapy Zolgensma are up 155 percent, the U.S. market, the first-time market, is not ideal, with full-year sales of only $459 million in 2020. Ma officially entered the U.S. market in June 2019, with sales of $361 million in just over six months, compared with less than $100 million for the whole of 2020 compared to more than six months in 2019.
155 per cent growth in Zolgensma's global sales may have benefited more from Japan's entry into health care and its entry into The European market.